Recent Finacing
Recent Raise
EpiBiologics develops tissue-selective bispecific antibodies that degrade extracellular protein targets to treat oncology and immunology diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at EpiBiologics.
